About this trial
The primary aim of this study is to develop a recommended clinical practice guideline for managing women with HPV HR (high-risk human papillomavirus) positivity and cervical lesions. Additionally, in collaboration with the Bioptic Laboratory, the study will analyze the integration of HPV HR testing into screening programs for women aged 35, 45, and 55, with a focus on optimizing management strategies for HPV HR-positive women.
Research Objectives:
* Evaluate spontaneous regression/progression over two years based on HPV HR genotyping (three groups - according to Alinity: high, intermediate, and low risk). * Assess spontaneous regression/progression over two years based on HPV HR genotyping and viral load in HPV-vaccinated vs. non-vaccinated patients. * Evaluate spontaneous regression/progression over two years based on methylation results. * Assess spontaneous regression/progression over two years based on CinTec plus results.
Eligibility criteria
Qualifiers
Informed Consent
cervical biopsy - HG lesion
Age: 18-46 years
colposcopicaly visible transformation zone
Disqualifiers
cytology AIS, AGC NEO, adenocarcinoma, squamous cell carcinoma
immunosuppression
active autoimmune disease
history of cervical cryodestruction
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Nikola Janovska
Lead sponsor
Faculty Hospital Kralovske Vinohrady
Sponsor institution